Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Electron transfer from singlet fission dimers: possibilities and limitations.

Chemical science·2026

Same author

Remotely Tuned Triplet Transfer via Ligand Proximity in Quantum Dot-Organic Spectral Converters.

ACS nano·2026

Same author

Key Roles of Aliphatic Ligands over PbS Quantum Dots for Efficient Triplet Energy Transfer in a Hybrid TES-ADT/PbS System for Triplet-Triplet Annihilation Photon Upconversion.

The journal of physical chemistry. C, Nanomaterials and interfaces·2026

Same author

Correction to "Improving Triplet-Triplet Annihilation Upconversion Output by a Triplet Mediator Approach: Mechanistic Insights on Homo- and Hetero-Annihilation in Three-Component Systems".

Journal of the American Chemical Society·2026

Same author

Stereotactic ablative radiotherapy-driven immunosuppression is associated with poorer progression-free survival in cancer patients.

Cancer immunology, immunotherapy : CII·2025

Same author

Improving Triplet-Triplet Annihilation Upconversion Output by a Triplet Mediator Approach: Mechanistic Insights on Homo and Hetero-Annihilation in Three-Component Systems.

Journal of the American Chemical Society·2025

Same journal

Present and Emerging Strategies for Disease Assessment in Hodgkin Lymphoma.

Cancer journal (Sudbury, Mass.)·2026

Same journal

Nodular Lymphocyte-predominant Hodgkin Lymphoma: Incidence, Pathogenesis, Management.

Cancer journal (Sudbury, Mass.)·2026

Same journal

Management of Classic Hodgkin Lymphoma in Special Clinical Situations.

Cancer journal (Sudbury, Mass.)·2026

Same journal

Older Patients With Hodgkin Lymphoma: A Contemporary Review.

Cancer journal (Sudbury, Mass.)·2026

Same journal

Adolescent and Young Adult Patients With Classical Hodgkin Lymphoma: A Review as a Case Study in AYA Cancer Care.

Cancer journal (Sudbury, Mass.)·2026

Same journal

Hodgkin Lymphoma: Management of Patients Who Fail Primary Therapy.

Cancer journal (Sudbury, Mass.)·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Sep 12, 2025

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Published on: April 5, 2024

Modulating Purinergic Signaling to Improve Radiotherapy Outcomes.

Jessica Oliver¹, Victor Gray, Linda S Li

¹Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.

Cancer Journal (Sudbury, Mass.)

|August 6, 2025

Summary

This summary is machine-generated.

Radiotherapy can stimulate anti-cancer immunity by releasing extracellular ATP and NAD. Understanding how these signals affect tumors is key to improving cancer treatment with immunotherapy.

Keywords:

P2X7 receptor Purinergic signalling adenosine immune escape immunotherapy radiotherapy tumour microenvironment

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Related Experiment Videos

Last Updated: Sep 12, 2025

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Published on: April 5, 2024

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Area of Science:

Immunology
Oncology
Radiotherapy

Background:

Radiotherapy's immunomodulatory effects are increasingly recognized, opening new avenues for cancer treatment.
Extracellular ATP and NAD act as danger signals, alerting the immune system.
Cancer disrupts the sensing and breakdown of these signals, impacting anti-tumor immunity.

Purpose of the Study:

To review the dual role of extracellular ATP and NAD in tumor immunity.
To discuss their impact on radiation-induced immune responses.
To explore therapeutic opportunities for targeting purinergic signaling in cancer radiotherapy.

Main Methods:

Literature review of purinergic signaling in cancer and radiotherapy.
Analysis of immunostimulatory and immunosuppressive mechanisms of ATP and NAD.
Discussion of current research and future directions.

Main Results:

Extracellular ATP and NAD can both stimulate and suppress anti-tumor immune responses.
Their signaling pathways are altered in the tumor microenvironment.
Targeting these purinergic signals presents a promising strategy to enhance radiotherapy efficacy.

Conclusions:

Purinergic signaling plays a critical, yet complex, role in radiation-induced immunity.
Further research is needed to fully elucidate these mechanisms.
Targeting extracellular ATP and NAD metabolism holds potential for improving cancer patient outcomes when combined with radiotherapy.